Vicuron (NASDAQ:MICU)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Vicuron Charts. Click Here for more Vicuron Charts.](/p.php?pid=staticchart&s=N%5EMICU&p=8&t=15)
Vicuron Pharmaceuticals Announces Pricing of $70.8 Million Public
Offering
KING OF PRUSSIA, Pa., Sept. 30 /PRNewswire-FirstCall/ -- Vicuron
Pharmaceuticals Inc. (Nasdaq: MICU; Nuovo Mercato), today announced that it has
priced a public offering of 4,800,000 shares of its common stock at $14.75 per
share, for a total offering amount of approximately $70.8 million. Vicuron has
granted the underwriter an option, exercisable for 30 days, to purchase up to
720,000 additional shares of its newly issued common stock to cover
over-allotments, if any.
Morgan Stanley is acting as the sole underwriter of the offering.
This press release shall not constitute an offer to sell or the solicitation of
an offer to buy any of these securities. The offering is being made solely by
means of a prospectus dated March 15, 2004 and the accompanying prospectus
supplement dated September 29, 2004. There shall not be any sale of these
securities in any state in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
any such state.
Copies of the prospectus and prospectus supplement relating to the public
offering may be obtained from Morgan Stanley, Attention: Prospectus
Department, 1585 Broadway, New York, New York, 10036, telephone 212-761-6775.
About Vicuron
Vicuron Pharmaceuticals is a biopharmaceutical company focused on discovering,
developing, manufacturing and commercializing vital medicine for seriously ill
patients.
Forward-Looking Statements
This news release contains forward-looking statements that predict or describe
future events or trends. The matters described in these forward-looking
statements are subject to known and unknown risks, uncertainties and other
unpredictable factors, many of which are beyond Vicuron's control. Vicuron
faces many risks that could cause its actual performance to differ materially
from the results predicted by its forward-looking statements, including the
possibilities that the above-mentioned public offering may be delayed or
cancelled, that clinical trials and the results thereof might be delayed or
unsuccessful, that the timing of the filing of any new drug application or any
amendment to a new drug application might be delayed, that clinical trials
might indicate that a product candidate is unsafe or ineffective, that the FDA
might require additional information to be submitted and additional actions to
be taken before it will make any decision, that any filed new drug application
may not be approved by the FDA, that ongoing proprietary and collaborative
research might not occur or yield useful results, that a third party may not be
willing to license our product candidates on terms acceptable to us or at all,
that competitors might develop superior substitutes for Vicuron's products or
market these competitive products more effectively, that a sales force may not
be developed as contemplated and that one or more of Vicuron's product
candidates may not be commercialized successfully. The reports that Vicuron
files with the U.S. Securities and Exchange Commission contain a fuller
description of these and many other risks to which Vicuron is subject. Because
of those risks, Vicuron's actual results, performance or achievements may
differ materially from the results, performance or achievements contemplated by
its forward-looking statement. The information set forth in this news release
represents management's current expectations and intentions. Vicuron assumes
no responsibility to issue updates to the forward-looking matters discussed in
this news release.
DATASOURCE: Vicuron Pharmaceuticals Inc.
CONTACT: Dov A. Goldstein, M.D. of Vicuron Pharmaceuticals Inc.,
+1-610-205-2312, or ; or Hala Bashir of WeissComm
Partners, +1-212-204-2080, or ; or Aline Schimmel of
Burns McClellan Inc., +1-212-213-0006, or , both for
Vicuron Pharmaceuticals Inc.
Web site: http://www.vicuron.com/